Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Immatics NV - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
IMTX
Nasdaq
8731
https://immatics.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Immatics NV
Immatics Announces Full Year 2023 Financial Results and Corporate Update
- Mar 21st, 2024 11:00 am
With 52% institutional ownership, Immatics N.V. (NASDAQ:IMTX) is a favorite amongst the big guns
- Mar 15th, 2024 10:22 am
Immatics' (NASDAQ:IMTX) investors will be pleased with their notable 35% return over the last year
- Feb 3rd, 2024 2:13 pm
Immatics Announces Pricing of $175 Million Public Offering
- Jan 18th, 2024 1:30 am
Immatics Announces Proposed Public Offering
- Jan 17th, 2024 9:01 pm
DISCO Pharmaceuticals launches as the surfaceome company with EUR 20 Million in Seed Financing
- Jan 16th, 2024 8:59 am
Levicept Appoints Eliot Forster as CEO
- Nov 30th, 2023 9:00 am
Immatics Announces Third Quarter 2023 Financial Results and Business Update
- Nov 14th, 2023 12:00 pm
Immatics Reports Interim Clinical Data from ACTengine® IMA203 and IMA203CD8 TCR-T Monotherapies Targeting PRAME in an Ongoing Phase 1 Trial
- Nov 8th, 2023 12:00 pm
Immatics (NASDAQ:IMTX) Is In A Good Position To Deliver On Growth Plans
- Nov 2nd, 2023 6:47 pm
Immatics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for ACTengine® IMA203 TCR-T Monotherapy
- Oct 24th, 2023 11:00 am
Immatics N.V. (NASDAQ:IMTX) is definitely on the radar of institutional investors who own 47% of the company
- Sep 23rd, 2023 2:20 pm
Protalix BioTherapeutics Appoints Eliot Richard Forster, Ph.D. as Chairman of its Board of Directors
- Sep 12th, 2023 10:50 am
Moderna and Immatics Announce Strategic Multi-Platform Collaboration to Develop Innovative Oncology Therapeutics
- Sep 11th, 2023 11:00 am
Those who invested in Immatics (NASDAQ:IMTX) three years ago are up 27%
- Aug 27th, 2023 12:30 pm
Immatics Announces Second Quarter 2023 Financial Results and Business Update
- Aug 17th, 2023 11:00 am
Immatics Initiates Phase 1/2 Clinical Trial to Evaluate PRAME TCR Bispecific IMA402 in Patients with Advanced Solid Tumors
- Aug 10th, 2023 11:00 am
Immatics Announces $35 Million Equity Investment from Bristol Myers Squibb
- Jul 24th, 2023 11:00 am
Immatics Announces First Quarter 2023 Financial Results and Business Update
- May 16th, 2023 11:00 am
Immatics Reports Interim Clinical Data from Ongoing Phase 1b Cohort A Monotherapy with ACTengine® IMA203 TCR-T Targeting PRAME
- May 2nd, 2023 11:00 am
Scroll